Prestige Consumer Healthcare (NYSE:PBH) Price Target Raised to $97.00

Prestige Consumer Healthcare (NYSE:PBH) had its target price upped by Royal Bank of Canada from $96.00 to $97.00 in a report published on Friday morning,Benzinga reports. They currently have a sector perform rating on the stock.

A number of other research analysts have also recently issued reports on PBH. Oppenheimer lifted their price objective on shares of Prestige Consumer Healthcare from $87.00 to $93.00 and gave the company an “outperform” rating in a report on Thursday, February 13th. Canaccord Genuity Group boosted their price target on shares of Prestige Consumer Healthcare from $93.00 to $100.00 and gave the stock a “buy” rating in a report on Friday, February 7th. Raymond James upgraded shares of Prestige Consumer Healthcare to a “moderate buy” rating in a report on Thursday, December 19th. DA Davidson boosted their price target on shares of Prestige Consumer Healthcare from $95.00 to $104.00 and gave the stock a “buy” rating in a report on Friday, February 7th. Finally, Sidoti cut shares of Prestige Consumer Healthcare from a “buy” rating to a “neutral” rating and set a $90.00 price target on the stock. in a report on Monday, December 9th. Three investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to MarketBeat.com, Prestige Consumer Healthcare presently has a consensus rating of “Moderate Buy” and a consensus target price of $93.33.

Prestige Consumer Healthcare Trading Down 0.3 %

PBH opened at $84.12 on Friday. Prestige Consumer Healthcare has a 1-year low of $62.35 and a 1-year high of $90.04. The company has a current ratio of 3.68, a quick ratio of 2.20 and a debt-to-equity ratio of 0.56. The company has a market cap of $4.17 billion, a P/E ratio of 19.70, a price-to-earnings-growth ratio of 2.69 and a beta of 0.46. The company has a fifty day moving average price of $82.46 and a two-hundred day moving average price of $78.64.

Prestige Consumer Healthcare (NYSE:PBH) last issued its quarterly earnings data on Thursday, February 6th. The company reported $1.22 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.18 by $0.04. Prestige Consumer Healthcare had a net margin of 19.13% and a return on equity of 12.36%. Analysts predict that Prestige Consumer Healthcare will post 4.5 EPS for the current fiscal year.

Insider Buying and Selling at Prestige Consumer Healthcare

In other Prestige Consumer Healthcare news, SVP Mary Beth Fritz sold 1,678 shares of the business’s stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $90.00, for a total value of $151,020.00. Following the transaction, the senior vice president now directly owns 17,157 shares in the company, valued at $1,544,130. The trade was a 8.91 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 1.60% of the company’s stock.

Institutional Trading of Prestige Consumer Healthcare

Hedge funds and other institutional investors have recently modified their holdings of the business. Kestra Investment Management LLC bought a new stake in shares of Prestige Consumer Healthcare in the fourth quarter valued at approximately $27,000. CIBC Private Wealth Group LLC raised its position in shares of Prestige Consumer Healthcare by 48.9% in the fourth quarter. CIBC Private Wealth Group LLC now owns 463 shares of the company’s stock valued at $34,000 after purchasing an additional 152 shares during the period. Headlands Technologies LLC bought a new stake in shares of Prestige Consumer Healthcare in the fourth quarter valued at approximately $40,000. McIlrath & Eck LLC raised its position in shares of Prestige Consumer Healthcare by 19.1% in the fourth quarter. McIlrath & Eck LLC now owns 959 shares of the company’s stock valued at $75,000 after purchasing an additional 154 shares during the period. Finally, Johnson Financial Group Inc. bought a new stake in shares of Prestige Consumer Healthcare in the fourth quarter valued at approximately $93,000. Institutional investors own 99.95% of the company’s stock.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.